Zepbound achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks

INDIANAPOLIS, Dec. 11, 2023.  Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials